Immune Response Corp. to Test AIDS Drug

Immune Response Corp. said it will begin tests of its AIDS drug Remune in combination with drugs developed by Glaxo Wellcome and Merck & Co. Researchers will study the effect on patients of combining Remune with Merck’s drug crixivan and Glaxo’s drugs, AZT and 3TC. That trial will be compared with a study of Remune on its own and a combination of AZT, 3TC and crixivan. As many as 150 patients will be involved in the studies, Immune Response said. Whereas AZT, 3TC and crixivan attack the AIDS virus, Remune stimulates a patient’s own immune system to attack the cells that manufacture the virus, the company said. Carlsbad-based Immune Response shares rose 37.5 cents to $7.875 on Nasdaq.C